465 related articles for article (PubMed ID: 24780112)
1. Neoadjuvant chemo-immunotherapy modifies CD4(+)CD25(+) regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients.
Pircher A; Gamerith G; Amann A; Reinold S; Popper H; Gächter A; Pall G; Wöll E; Jamnig H; Gastl G; Wolf AM; Hilbe W; Wolf D
Lung Cancer; 2014 Jul; 85(1):81-7. PubMed ID: 24780112
[TBL] [Abstract][Full Text] [Related]
2. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
3. A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Yang YJ; Park JC; Kim HK; Kang JH; Park SY
Anticancer Res; 2013 May; 33(5):2115-22. PubMed ID: 23645763
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.
Jie HB; Schuler PJ; Lee SC; Srivastava RM; Argiris A; Ferrone S; Whiteside TL; Ferris RL
Cancer Res; 2015 Jun; 75(11):2200-10. PubMed ID: 25832655
[TBL] [Abstract][Full Text] [Related]
5. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
6. Changes of CD4+CD25+FOXP3+ and CD8+CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery.
Chen C; Chen D; Zhang Y; Chen Z; Zhu W; Zhang B; Wang Z; Le H
Int Immunopharmacol; 2014 Feb; 18(2):255-61. PubMed ID: 24345703
[TBL] [Abstract][Full Text] [Related]
7. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
9. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients.
Kimura H; Iizasa T; Ishikawa A; Shingyouji M; Yoshino M; Kimura M; Inada Y; Matsubayashi K
Anticancer Res; 2008; 28(2B):1229-38. PubMed ID: 18505060
[TBL] [Abstract][Full Text] [Related]
10. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study.
Ratto GB; Costa R; Maineri P; Alloisio A; Piras MT; D'Agostino A; Tripodi G; Rivabella L; Dozin B; Bruzzi P; Melioli G
Int J Immunopathol Pharmacol; 2011; 24(4):1005-16. PubMed ID: 22230406
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
[TBL] [Abstract][Full Text] [Related]
12. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
13. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC).
Erfani N; Mehrabadi SM; Ghayumi MA; Haghshenas MR; Mojtahedi Z; Ghaderi A; Amani D
Lung Cancer; 2012 Aug; 77(2):306-11. PubMed ID: 22608141
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation.
Zhang G; Zhao H; Wu J; Li J; Xiang Y; Wang G; Wu L; Jiao S
Int Immunopharmacol; 2014 Aug; 21(2):396-405. PubMed ID: 24881900
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
[TBL] [Abstract][Full Text] [Related]
16. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
Aydiner A; Sen F; Saglam EK; Oral EN; Eralp Y; Tas F; Toker A; Dilege S
Clin Lung Cancer; 2011 Sep; 12(5):286-92. PubMed ID: 21729649
[TBL] [Abstract][Full Text] [Related]
18. Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer.
Esendagli G; Bruderek K; Goldmann T; Busche A; Branscheid D; Vollmer E; Brandau S
Lung Cancer; 2008 Jan; 59(1):32-40. PubMed ID: 17825949
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic outcomes of combining cryotherapy, chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer.
Yuanying Y; Lizhi N; Feng M; Xiaohua W; Jianying Z; Fei Y; Feng J; Lihua H; Jibing C; Jialiang L; Kecheng X
Cryobiology; 2013 Oct; 67(2):235-40. PubMed ID: 23948179
[TBL] [Abstract][Full Text] [Related]
20. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas.
Kayser G; Schulte-Uentrop L; Sienel W; Werner M; Fisch P; Passlick B; Zur Hausen A; Stremmel C
Lung Cancer; 2012 Jun; 76(3):445-51. PubMed ID: 22300751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
